SCHEMBL6647334

SCHEMBL6647334

CN(C)C1CCN(c2cc3c(Cl)cccc3c(=O)[nH]2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 5/20 0.47
PARP1 P09874 3/20 0.47
WEE1 P30291 5/20 0.41
APAF1 O14727 1/20 0.40
CDC25B P30305 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
PTPN11 Q06124 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SETD2 Q9BYW2 2/20 0.37
NSD2 O96028 1/20 0.37
SLC6A4 P31645 1/20 0.36
PDGFRB P09619 1/20 0.36
FGFR1 P11362 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6648367 0.86 TNKS (0.59) TNKSPARP1APAF1CDC25BCASP3
SCHEMBL6645174 0.85 SETD2 (0.46) TNKSPARP1WEE1APAF1CDC25B
SCHEMBL6643880 0.85 PARP1 (0.47) TNKSPARP1APAF1CDC25BCASP3
SCHEMBL6646307 0.85 PARP1 (0.48) TNKSPARP1APAF1CDC25BCASP3
SCHEMBL6646697 0.85 PARP1 (0.45) TNKSPARP1WEE1APAF1CDC25B
SCHEMBL6643163 0.84 SETD2 (0.40) TNKSPARP1WEE1APAF1CDC25B
SCHEMBL6645853 0.83 PARP1 (0.44) TNKSPARP1APAF1CDC25BCASP3
SCHEMBL6643130 0.83 TNKS (0.45) TNKSPARP1APAF1CDC25BCASP3
SCHEMBL6647905 0.83 PARP1 (0.44) TNKSPARP1WEE1APAF1CDC25B
SCHEMBL6643846 0.82 PARP1 (0.43) TNKSPARP1WEE1APAF1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US claimed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP claimed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 TNKS 121/4885PARP1 2/4885WEE1 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.